Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia
Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia - a Phase 4 Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, South Korea
- Jin-Tae Kim
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients scheduled for elective knee or hip arthroplasty under spinal anesthesia
- BMI>25
- American Society of Anesthesiologists (ASA) classification I, II, III
Exclusion Criteria:
- Patient refusal
- Contraindication for spinal anesthesia
- Contraindication for remimazolam infusion
- History of hypersensitivity to remimazolam
- History of chronic use of benzodiazepine or opioid
- Baseline MOAA/S score of 4 or lower
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ideal body weight group
|
0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0
mg/kg/h based on ideal or total body weight
|
|
Active Comparator: Total body weight group
|
0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0
mg/kg/h based on ideal or total body weight
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of intraoperative respiratory depression
Time Frame: From entrance to exit from the operating room
|
Incidence of intraoperative respiratory depression
|
From entrance to exit from the operating room
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total remimazolam infusion dose
Time Frame: From start to end of remimazolam infusion
|
Total remimazolam infusion dose (mg/kg/h)
|
From start to end of remimazolam infusion
|
|
Incidence of intraoperative hypotension
Time Frame: From entrance to exit from the operating room
|
Mean blood pressure <65 mmHg
|
From entrance to exit from the operating room
|
|
Incidence of intraoperative hypertension
Time Frame: From entrance to exit from the operating room
|
Systolic blood pressure >120% of baseline
|
From entrance to exit from the operating room
|
|
Incidence of intraoperative bradycardia
Time Frame: From entrance to exit from the operating room
|
Heart rate <45 bpm
|
From entrance to exit from the operating room
|
|
Incidence of intraoperative tachycardia
Time Frame: From entrance to exit from the operating room
|
Heart rate >120 bpm
|
From entrance to exit from the operating room
|
|
Incidence of intraoperative oxygen desaturation
Time Frame: From entrance to exit from the operating room
|
Pulse oximeter saturation (SpO2) < 93%
|
From entrance to exit from the operating room
|
|
Incidence of intraoperative nausea or vomiting
Time Frame: From entrance to exit from the operating room
|
Nausea or vomiting during surgery
|
From entrance to exit from the operating room
|
|
Incidence of intraoperative hiccups
Time Frame: From entrance to exit from the operating room
|
Hiccups during surgery
|
From entrance to exit from the operating room
|
|
Incidence of intraoperative paradoxical movements
Time Frame: From entrance to exit from the operating room
|
Paradoxical movements during surgery
|
From entrance to exit from the operating room
|
|
Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score
Time Frame: From start of remimazolam infusion until time of full alertness
|
MOAA/S score assessment at 10 min intervals
|
From start of remimazolam infusion until time of full alertness
|
|
Intraoperative Patient State Index (PSi)
Time Frame: From entrance to exit from the operating room
|
Continuous monitoring of PSi with Sedline sensor
|
From entrance to exit from the operating room
|
|
Time to reach MOAA/S score 5 after end of surgery
Time Frame: From end of remimazolam infusion until time of full alertness
|
Time to reach MOAA/S score 5 (min)
|
From end of remimazolam infusion until time of full alertness
|
|
Length of stay at the post-anesthesia care unit (PACU)
Time Frame: From entrance to exit from the PACU
|
Length of stay at the PACU (min)
|
From entrance to exit from the PACU
|
|
Patient satisfaction
Time Frame: At exit from PACU
|
Numeric rating scale of 0 (not satisfied at all) to 10 (absolutely satisfied)
|
At exit from PACU
|
|
Intraoperative recall
Time Frame: At exit from PACU
|
Assessment with the modified Brice questionnaire
|
At exit from PACU
|
|
Incidence of postoperative nausea or vomiting
Time Frame: From entrance to exit from the PACU
|
Incidence of nausea or vomiting
|
From entrance to exit from the PACU
|
|
Incidence of postoperative delirium
Time Frame: From end of surgery to third postoperative day
|
Assessment with the Confusion Assessment Method (CAM)
|
From end of surgery to third postoperative day
|
|
Incidence of postoperative respiratory depression
Time Frame: From entrance to exit from the PACU
|
Respiratory rate < 8/min or SpO2<93%
|
From entrance to exit from the PACU
|
|
Incidence of postoperative hypotension
Time Frame: From entrance to exit from the PACU
|
Mean blood pressure <65 mmHg
|
From entrance to exit from the PACU
|
|
Incidence of postoperative hypertension
Time Frame: From entrance to exit from the PACU
|
Systolic blood pressure >120% from baseline
|
From entrance to exit from the PACU
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jin-Tae Kim, M.D., Ph.D., Seoul National University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H-2301-016-1391
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.